Clinical Trial Update: Dalpiciclib With Endocrine Therapy for Advanced Breast Cancer After CDK4/6 Inhibitor Failure (DAWNA-FES) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating dalpiciclib with endocrine therapy for advanced breast cancer after failure of CDK4/6 inhibitors is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Dalpiciclib (dalpiciclib)
• Endocrine therapy

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Advanced Breast Cancer | Phase 3 | Status: RECRUITING